Article
Nivolumab Effective in Peviously Treated RCC Patients
The authors however cautioned that we still lack an understanding of biomarker-driven patient selection for PD-1 and PD-L1 agent. Adequate knowledge of the mechanism of action of these immuno-oncology agents could help optimize therapy, they add.
After a median follow-up of 45 months, the anti—PD-1 antibody nivolumab showed benefit in a majority of patients who had previously received 1 to 5 treatments for renal cell carcinoma, according to a report published online March 23 in the Journal of Clinical Oncology.
The previously treated cohort included 71% who had received 2 prior systemic treatments and 44% who had received three or more prior treatments for renal cell carcinoma. Out of the total 34 patients, 10 (29%) had objective responses, 9 (27%) had stable disease for at least 24 weeks, 2 (6%) had stable disease for at least 48 weeks, and 3 patients (9%) had unconventional immune-related responses, which can include reduction in target lesions in the presence of new lesions or regression after initial progression.
Complete article on Oncology Practice: http://bit.ly/18WV9bo
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
